Get the Stockscreener App
13.00
5.93%
-0.82
Bicara Therapeutics Inc stock is traded at $13.00, with a volume of 351.34K.
It is down -5.93% in the last 24 hours and up +7.62% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$13.82
Open:
$14.01
24h Volume:
351.34K
Relative Volume:
0.87
Market Cap:
$707.40M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.56%
1M Performance:
+7.62%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.69
$14.13
1-Week Range:
$12.38
$14.42
52-Week Range:
$11.10
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-785-8308
Address
245 MAIN STREET, CAMBRIDGE
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
13.00 | 707.40M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts - Defense World
Bicara Therapeutic, Inc. announced that it has received $108.234983 million in funding from a group of investors - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.6%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.3%Should You Buy? - MarketBeat
Wedbush Reiterates Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Announces First Patients Enrolled in - GlobeNewswire
Major Cancer Treatment Breakthrough? Phase 2/3 Trial Launches for Advanced Head & Neck Cancer - StockTitan
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to Strong-Buy at Wedbush - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Wedbush - MarketBeat
Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to “Strong-Buy” - Armenian Reporter
Bicara Therapeutics (BCAX) to Release Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - Nasdaq
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha
H.C. Wainwright lifts Bicara stock target to $45, maintains buy - MSN
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowTime to Sell? - MarketBeat
Bicara Therapeutics price target raised to $45 from $42 at H.C. Wainwright - MSN
Bicara Therapeutics Presents Phase 1/1B Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Stifel maintains Buy on Bicara stock with $47 target By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 at HC Wainwright - Defense World
Bicara reports positive Phase 1/1b trial results for cancer therapy By Investing.com - Investing.com South Africa
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up After Analyst Upgrade - Defense World
Bicara Therapeutics Presents Phase 1/1b Dose Expansion - GlobeNewswire
Stifel maintains Buy on Bicara stock with $47 target - Investing.com India
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up on Analyst Upgrade - MarketBeat
H.C. Wainwright lifts Bicara stock target to $45, maintains buy By Investing.com - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 - MarketBeat
Cantor Fitzgerald Weighs in on BCAX FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on BCAX FY2025 Earnings - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average Price Target from Analysts - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flynn James E | Possible Members of 10% Group |
Sep 17 '24 |
Buy |
18.00 |
70,000 |
1,260,000 |
897,587 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):